MANILA, Jan 31 (Reuters) - At least 5.6 million COVID-19
doses of two international COVID-19 vaccines are expected to
arrive in the Philippines in the first quarter of the year, the
chief of the country's coronavirus task force said on Sunday.
The initial volume is part of the 9.4 million doses of the
two vaccines - one developed by Pfizer Inc PFE.N and BioNTech
SE 22UAy.DE , the other by AstraZeneca PLC AZN.L - that are
expected to be shipped in the first half, said Carlito Galvez,
who also handles the government's vaccine procurement.
Galvez said he has received a letter from Aurelia Nguyen,
managing director of the World Health Organization-led COVAX
Facility, informing the Philippine government of the shipment
schedule and volume.
Review committees from the WHO, UNICEF and the Geneva-based
vaccine alliance GAVI granted the country the vaccines after the
Philippines demonstrated its preparedness to receive them, he
said.
The country's Food and Drug Administration has approved the
emergency use of both brands. The Philippines, with Southeast Asia's second-biggest
COVID-19 outbreak at more than half a million infections and
over 10,000 deaths, aims to start immunisations in February.
The country is to initially receive 117,000 doses of the
Pfizer-BioNTech vaccine around midmonth, and 5.5 million to 9.3
million doses of the AstraZeneca brand, Galvez said.
The volumes though are "indicative since it all depends on
the global supply", he said.
The government aims to secure 148 million doses, aiming to
inoculate 70 million people this year, or two-thirds of the
country's population.
The Philippines has also secured 25 million doses of the
vaccine developed by China's Sinovac Biotech, with the first
50,000 expected to arrive in February.
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Philippines expects 5.6 mln COVID-19 vaccine doses to arrive by end-March
Published 01/31/2021, 05:32 PM
Updated 01/31/2021, 05:40 PM
Philippines expects 5.6 mln COVID-19 vaccine doses to arrive by end-March
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Latest comments
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.